Jacobio Pharmaceuticals Group Management
Management criteria checks 3/4
Jacobio Pharmaceuticals Group's CEO is Yinxiang Wang, appointed in Aug 2019, has a tenure of 5.33 years. total yearly compensation is CN¥3.42M, comprised of 77.3% salary and 22.7% bonuses, including company stock and options. directly owns 13.63% of the company’s shares, worth HK$139.82M. The average tenure of the management team and the board of directors is 4.9 years and 4.3 years respectively.
Key information
Yinxiang Wang
Chief executive officer
CN¥3.4m
Total compensation
| CEO salary percentage | 77.3% |
| CEO tenure | 5.3yrs |
| CEO ownership | 13.6% |
| Management average tenure | 4.9yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
Does Jacobio Pharmaceuticals Group (HKG:1167) Have A Healthy Balance Sheet?
Nov 24
Most Shareholders Will Probably Agree With Jacobio Pharmaceuticals Group Co., Ltd.'s (HKG:1167) CEO Compensation
May 31Is Jacobio Pharmaceuticals Group (HKG:1167) Using Debt Sensibly?
May 29We're Hopeful That Jacobio Pharmaceuticals Group (HKG:1167) Will Use Its Cash Wisely
May 10Time To Worry? Analysts Are Downgrading Their Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Outlook
Aug 26We're Not Very Worried About Jacobio Pharmaceuticals Group's (HKG:1167) Cash Burn Rate
Jul 29We Think Jacobio Pharmaceuticals Group (HKG:1167) Can Afford To Drive Business Growth
Apr 29What Percentage Of Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Shares Do Insiders Own?
Mar 21CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -CN¥362m |
| Mar 31 2024 | n/a | n/a | -CN¥361m |
| Dec 31 2023 | CN¥3m | CN¥3m | -CN¥359m |
| Sep 30 2023 | n/a | n/a | -CN¥385m |
| Jun 30 2023 | n/a | n/a | -CN¥410m |
| Mar 31 2023 | n/a | n/a | -CN¥391m |
| Dec 31 2022 | CN¥4m | CN¥2m | -CN¥372m |
| Sep 30 2022 | n/a | n/a | -CN¥332m |
| Jun 30 2022 | n/a | n/a | -CN¥292m |
| Mar 31 2022 | n/a | n/a | -CN¥297m |
| Dec 31 2021 | CN¥4m | CN¥2m | -CN¥301m |
Compensation vs Market: Yinxiang's total compensation ($USD467.92K) is above average for companies of similar size in the Hong Kong market ($USD231.54K).
Compensation vs Earnings: Yinxiang's compensation has been consistent with company performance over the past year.
CEO
Yinxiang Wang (59 yo)
5.3yrs
Tenure
CN¥3,415,000
Compensation
Dr. Yinxiang Wang serves as Consultant at Shining Capital. He is an Executive Chairman at Jacobio Pharmaceuticals Co. Ltd. since August 20, 2020.Dr. Wang has been Director at Jacobio Pharmaceuticals Co. L...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman & CEO | 5.3yrs | CN¥3.42m | 13.63% HK$ 139.8m | |
| Executive Director & President of Administration | 9.3yrs | CN¥2.55m | 2.91% HK$ 29.8m | |
| Executive VP & Executive Director | 5.8yrs | CN¥2.51m | 2.95% HK$ 30.3m | |
| Vice President of Human Resources | no data | no data | no data | |
| Executive VP | 4.4yrs | no data | no data | |
| Executive Vice President of Non-Clinical R&D | no data | no data | no data | |
| Senior Vice President of Information & Data Management | no data | no data | no data | |
| Executive Vice President of Clinical Development | no data | no data | no data | |
| Joint Company Secretary | 4.3yrs | no data | no data | |
| Joint Company Secretary | 2.3yrs | no data | no data |
4.9yrs
Average Tenure
56yo
Average Age
Experienced Management: 1167's management team is considered experienced (4.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman & CEO | 6.5yrs | CN¥3.42m | 13.63% HK$ 139.8m | |
| Executive Director & President of Administration | 6.4yrs | CN¥2.55m | 2.91% HK$ 29.8m | |
| Executive VP & Executive Director | 6.4yrs | CN¥2.51m | 2.95% HK$ 30.3m | |
| Independent Non-Executive Director | 4.3yrs | CN¥200.00k | no data | |
| Independent Non-Executive Director | 4.3yrs | CN¥400.00k | no data | |
| Non Executive Director | 4.3yrs | no data | no data | |
| Independent Non-Executive Director | 1.8yrs | CN¥150.00k | no data |
4.3yrs
Average Tenure
60yo
Average Age
Experienced Board: 1167's board of directors are considered experienced (4.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 12:08 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jacobio Pharmaceuticals Group Co., Ltd. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ziyi Chen | Goldman Sachs |